• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·603858.SS
Share

Shandong Buchang Pharmaceuticals Co., Ltd. Stocks

CN¥ 15.82Last Updated 13.07.2026

Issuer Rating

4/7
Performance

Modest

Risk

Low

Recommendation

Hold

Market Cap

CN¥ 2.41B

CN¥ 15.82
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shandong Buchang Pharmaceuticals Co., Ltd. is actively involved in China's pharmaceutical sector, specializing in the innovation, production, and distribution of medicinal products. The company provides a diverse range of treatments addressing various health conditions, including cardiovascular, cerebrovascular, urinary, digestive, and respiratory disorders, alongside gynecological problems and diabetes. Founded in 1993, this enterprise maintains its headquarters in Heze, China. Notably, it once operated as a subsidiary of Shanghai Zhangjiang (Group) Co., Ltd.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, o

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 02:42

Prosecutors from 12 U.S. states have filed a lawsuit against the Paramount-Warner Bros. Discovery deal

14.07.2026 01:22

SK Hynix Led the Decline Among Chipmakers; Oil Prices Suffered Their Sharpest One-Day Drop Since 2020

14.07.2026 00:44

Oil prices jumped by nearly 10%. The price of Brent crude exceeded $83 per barrel

14.07.2026 00:19

The top-performing stock in the S&P 500 has risen 600% this year. Evercore expects it to rise another 80%.

13.07.2026 23:47

Investors' bets on AI have bolstered the dollar. Why has this now become a risk for the currency?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026